Discuss Abbott Laboratories
Abbott Laboratories
WKN: 850103 / Symbol: ABT / Name: Abbott / Aktie / Pharmazeutika / Large Cap /
106,88 €
0,97 %
Abbott Laboratories (NYSE: ABT) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $145.00 price target on the stock, up previously from $143.00.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Raymond James Financial, Inc. from $142.00 to $141.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Wells Fargo & Company from $147.00 to $142.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) was upgraded by analysts at William Blair to a "strong-buy" rating.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $153.00 to $157.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Evercore ISI from $140.00 to $144.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) is now covered by analysts at Benchmark Co.. They set a "buy" rating and a $145.00 price target on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $145.00 price target on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at Evercore ISI from $144.00 to $142.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Raymond James Financial, Inc. from $141.00 to $146.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Sanford C. Bernstein from $145.00 to $150.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Jefferies Financial Group Inc. from $145.00 to $149.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Wells Fargo & Company from $142.00 to $146.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $147.00 price target on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Barclays PLC from $159.00 to $162.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Daiwa Capital Markets from $134.00 to $136.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $145.00 price target on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) was upgraded by analysts at William Blair to a "strong-buy" rating.
Ratings data for ABT provided by MarketBeat
Neueste Beiträge
Morgan_Stanley in Hasbro Inc. diskutieren